Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies

被引:22
|
作者
Tsai, Lester [1 ]
Nguyen, Nghia H. [1 ]
Ma, Christopher [2 ,3 ]
Prokop, Larry J. [4 ]
Sandborn, William J. [1 ]
Singh, Siddharth [1 ,5 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Gastroenterol, 9452 Med Ctr Dr,ACTRI 1W501, La Jolla, CA 92093 USA
[2] Univ Calgary, Dept Med, Div Gastroenterol & Hepatol, Calgary, AB, Canada
[3] Univ Calgary, Dept Community Hlth Sci, Div Gastroenterol & Hepatol, Calgary, AB, Canada
[4] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN USA
[5] Univ Calif San Diego, Div Biomed Informat, Dept Med, La Jolla, CA USA
关键词
Natural history; Complications; Inflammatory bowel diseases; Inpatient; Biologics; INFLAMMATORY-BOWEL-DISEASE; INCEPTION COHORT; MANAGEMENT; PREVALENCE; PREDICTORS; SURGERY; ERA;
D O I
10.1007/s10620-021-07200-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims Inflammatory bowel diseases (IBD) lead to high morbidity and unplanned healthcare utilization. We conducted a systematic review with meta-analysis to estimate the cumulative incidence of IBD-related (and all-cause) hospitalization in patients with ulcerative colitis (UC) and Crohn's disease (CD). Methods Through a systematic review to September 3, 2019, we identified population-based inception cohort studies in patients with IBD that reported patient-level cumulative incidence of hospitalization at 1, 3 and 5 years after diagnosis. Hospitalization risk was pooled using random effects meta-analysis, and risk factors analyzed through mixed-effects meta-regression and qualitative synthesis. Results In patients with UC (6 cohorts), 1-, 3- and 5-year risk of UC-related hospitalization was 10.4% (95% CI 8.2-13.2), 17.0% (95% CI 14.0-20.4) and 21.5% (95% CI 18.0-25.4), respectively, with considerable heterogeneity. In patients with CD (6 cohorts), 1-, 3- and 5-year risk of CD-related hospitalization was 29.3% (95% CI 20.0-40.8), 38.5% (95% CI 26.8-51.7) and 44.3% (95% CI 32.7-56.5), respectively, with considerable heterogeneity. On meta-regression, steady decline in risk of hospitalization was observed in patients diagnosed in a more contemporary era. Younger age at onset (both UC and CD), extensive colitis (UC), ileal-dominant CD, perianal CD and penetrating and/or stricturing behavior (CD) and early need for corticosteroids and immunosuppressive therapy (both UC and CD) were associated with increased risk of hospitalization. Conclusion Approximately one in five and one in two patients with UC and CD are hospitalized within 5 years of diagnosis, respectively. Population health management strategies are required to mitigate unplanned healthcare utilization.
引用
收藏
页码:2451 / 2461
页数:11
相关论文
共 50 条
  • [21] Differences in the prevalence of uveitis between Crohn's disease and ulcerative colitis: A systematic review and meta-analysis
    Lin, Haowen
    Zhang, Jiaqing
    Liang, Chen
    Wu, Dongxuan
    Tan, Yuan
    Luo, Lixia
    Liu, Zhenzhen
    ACTA OPHTHALMOLOGICA, 2024, 102 (04) : e485 - e492
  • [22] RISK OF PSORIASIS, CROHN'S DISEASE, ULCERATIVE COLITIS AND ANKYLOSING SPONDYLITIS IN PATIENTS WITH UVEITIS: A NATIONWIDE, POPULATION-BASED COHORT STUDY
    Chen, Hsin-Hua
    Hsieh, Tsu-Yi
    Lin, Ching-Heng
    Chen, Yi-Ming
    Lai, Kuo-Lung
    Chen, Der-Yuan
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 627 - 627
  • [23] Increased Risk for Dementia in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Studies
    Liu, Mengsi
    Li, Dongxiu
    Hong, Xia
    Sun, Zhen
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [24] Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis
    Odes, S.
    Vardi, H.
    Friger, M.
    Esser, D.
    Wolters, F.
    Moum, B.
    Waters, H.
    Elkjaer, M.
    Bernklev, T.
    Tsianos, E.
    O'Morain, C.
    Stockbrugger, R.
    Munkholm, P.
    Langholz, E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) : 735 - 744
  • [25] Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies
    Zamani, Mohammad
    Alizadeh-Tabari, Shaghayegh
    Murad, Mohammad Hassan
    Singh, Siddharth
    Ananthakrishnan, Ashwin N.
    Malekzadeh, Reza
    Talley, Nicholas J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1264 - 1275
  • [26] A comprehensive meta-analysis of the risk of colorectal cancer in ulcerative colitis and Crohn's disease
    Lutgens, Maurice W.
    van der Heijden, Geert J.
    Vleggaar, Frank P.
    Oldenburg, Bas
    GASTROENTEROLOGY, 2008, 134 (04) : A33 - A34
  • [27] Cumulative Incidence of Second Major Abdominal Surgery Crohn's Disease: A Systematic Review and Meta-analysis of Population-based Studies
    Frolkis, Alexandra
    Lipton, Debra
    Negron, Maria
    Dyekamn, Jonathan
    Fiest, Kirsten
    deBruyn, Jennifer
    Jette, Nathalie
    Panaccione, Remo
    Ghosh, Subrata
    Kaplan, Gilaad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S525 - S526
  • [28] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, M.
    Madsen, G. R.
    Bendtsen, F.
    Seidelin, J. B.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I483 - I484
  • [29] Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis
    Attauabi, Mohamed
    Madsen, Gorm Roager
    Bendtsen, Flemming
    Seidelin, Jakob Benedict
    Burisch, Johan
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (09) : 1168 - 1178
  • [30] SYSTEMATIC REVIEW AND META-ANALYSIS OF MUCOSAL HEALING OUTCOMES WITH BIOLOGICS IN TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
    Aggarwal, S.
    Kumar, S.
    Topaloglu, H.
    Bela, A.
    Topaloglu, O.
    VALUE IN HEALTH, 2022, 25 (12) : S41 - S41